Thank you.
Just one more time, Mr. Champoux, I appreciate the discussion on your particular point. One of the concerns I have is that maybe the big ones—maybe the biggest ones—have the ability to work with the CRTC and to provide that kind of information. My fear is that you're getting into a lot of the smaller platforms out there that creators go to. They may look at Canada and say, “We're not willing to go through this.” I'll give you an example.
We have Trikafta, which is a drug by a company called Vertex in the U.S. Because of the bureaucracy in Canada, or proposed bureaucracy, they will not yet bring that drug to Canada for cystic fibrosis patients, but it has a 90% cure rate.
Here's the other side of that. If we have a small market and we have a lot of creators who look to different types of smaller platforms, will they be willing to go through that kind of mechanism given their limited resources? We may lose out on platforms that creators could go to.